Trial · NCT00938964
Outcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change | Preoperative to 6 weeks after surgery | units on a scale | MEAN | |
| PRIMARY | Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome | Preoperative to 6 weeks after surgery | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Transcerebral Activation Gradients of Platelets | Baseline to 6 hours post cross-clamp removal | Planned substudy, that was analyzed after 202 enrolled subjects | Mean linear fluorescence intensity-MLFI | MEAN |
| SECONDARY | Transcerebral Activation Gradients of Neutrophils | Baseline to 6 hours post cross-clamp removal | Planned substudy, that was analyzed after 202 enrolled subjects | Mean linear fluorescence intensity-MLFI | MEAN |
| SECONDARY | Transcerebral Activation Gradients of Monocytes | Baseline to 6 hours post cross-clamp removal | Planned substudy, that was analyzed after 202 enrolled subjects. | Mean linear fluorescence intensity-MLFI | MEAN |
| SECONDARY | Transcerebral Activation Gradient of Platelet-neutrophil Conjugates | Baseline to 6 hours post cross-clamp removal | Planned substudy, that was analyzed after 202 enrolled subjects. | Mean linear fluorescence intensity-MLFI | MEAN |
| SECONDARY | Change in Cognitive Function From Baseline | 1 year after surgery | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in Duke Activity Status Index (DASI) | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in Duke Activity Status Index (DASI) | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS) | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in Center for Epidemiological Studies Depression Scale (CES-D) | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in Center for Epidemiological Studies Depression Scale (CES-D) | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in Spielberger State Anxiety Inventory (STAI) | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in Spielberger State Anxiety Inventory (STAI) | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in Symptom Limitations | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in Symptom Limitations | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | baseline, 6-weeks | units on a scale | MEAN | |
| SECONDARY | Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL) | baseline, 1-year | There was 26 lidocaine patients and 17 placebo patients lost to follow-up between the primary 6-week follow-up and the final 1-year follow-up time point. Only those returning for 1 year follow-up were included in the analysis. | units on a scale | MEAN |
| SECONDARY | Change in the Cognitive Difficulties Scale | baseline, 6-weeks | units on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00938964/outcomes